hematologic malignancies
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.
The company is gearing up to launch a new rapid NGS test for acute myeloid leukemia and a liquid biopsy comprehensive genomic profiling assay.
Bionano Genomics Upbeat on Further Clinical Adoption of Optical Genome Mapping With New CPT Code
Premium
The Category I CPT code paves the way for reimbursement of OGM-based clinical tests, though details on pricing and insurance coverage are still unclear.
Written by early OGM adopters, the framework describes best practices for the technology's clinical implementation for hematological malignancies.